GlycoNex Inc. and Nippon Kayaku Co., Ltd. enter collaboration to advance next-generation ADC candidate GNX201-ADC

CAR-T Digest - August 2020

23 March 2026: GlycoNex Inc. and Nippon Kayaku Co., Ltd. enter collaboration to advance next-generation ADC candidate GNX201-ADC

GlycoNex and Nippon Kayaku have entered into a strategic collaboration to advance GNX201-ADC, a next-generation antibody-drug conjugate targeting solid tumors
Under this agreement, both companies will jointly drive preclinical development, focusing on optimizing the ADC design and generating data to support future clinical studies
GNX201-ADC is designed as a protease-activated, tumor-selective ADC, remaining stable in circulation and becoming active only within the tumor microenvironment to enable targeted payload delivery
This mechanism is enabled by PrecisemAb Biotech’s Universal Antibody Lock platform, which allows controlled activation of the ADC and is intended to improve the therapeutic index by minimizing toxicity to normal tissues
Overall, the collaboration reflects a broader shift toward next-generation ADC strategies, including conditional activation and novel targeting approaches, to enhance efficacy and safety in solid tumors